Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study

Hoskins, Paul; Eisenhauer, Elizabeth; Vergote, Ignace; Dubuc-Lissoir, Josée; Fisher, B.; Grimshaw, Robert; Oza, Amit M.; Plante, Marie; Stuart, Gavin; Vermorken, Jan B.

doi:10.1200/jco.2000.18.24.4038

Cited by 60 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sequential doublet combination may minimize toxicities associated with the triplet regimen and reduce the likelihood that patients with topotecan-or paclitaxel-resistant tumors will fail to benefit from treatment. A number of phase I/II studies are investigating sequential topotecan/platinum and paclitaxel/platinum courses, and the results are summarized in Table 4 [37,38]. [36] paclitaxel 60 (over 1 hour) 6 doses × 2 courses, followed by regimen: CR = 32.4%, PR = 45.9%.…”

Section: Sequential Doublets Of Topotecan/paclitaxel With Platinummentioning

confidence: 99%

“…In an attempt to limit the toxicities associated with a three-drug combination, the National Cancer Institute of Canada Clinical Trials Group investigated the feasibility of administering topotecan along with carboplatin and paclitaxel in sequential couplets of cisplatin/topotecan, followed by paclitaxel/cisplatin, in 44 patients [37]. Cisplatin, 50 mg/m 2 , was administered on day 1, and topotecan, 0.75 mg/m 2 , on days 1 to 5, with cycles repeating every 21 days for four cycles.…”

Section: Sequential Doublets Of Topotecan/paclitaxel With Platinummentioning

confidence: 99%

See 1 more Smart Citation

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Coleman¹

2002

The Oncologist

View full text Add to dashboard Cite

The conventional front-line chemotherapy strategy for advanced epithelial ovarian carcinoma has become adjuvant administration of platinum (carboplatin and cisplatin), either alone or, most often, in combination with a taxane. However, a number of active agents have been identified in phase II/III trials of second-line and salvage ovarian cancer patients that may augment this front-line strategy. One agent, topotecan, has antitumor activity comparable with paclitaxel in patients with recurrent ovarian cancer and is an established treatment in secondline or salvage settings. Additionally, its mechanism of action is different from paclitaxel and is nonoverlapping. These properties, coupled with the in vitro synergy observed in tumor models among topotecan, paclitaxel, and platinum, have provided the rationale for investigators to examine topotecan in front-line ovarian cancer therapy. A number of strategies for incorporating topotecan into front-line therapy are under active investigation, including the replacement of paclitaxel with topotecan, a triplet regimen with cisplatin or carboplatin and paclitaxel, a consolidation regimen consisting of several courses of a platinum agent and paclitaxel followed by several courses of topotecan, and a sequential doublet regimen in which patients receive platinum in every course as part of a doublet with alternating or sequential topotecan and paclitaxel. Preliminary data from ongoing clinical trials of these new regimens show favorable response rates and generally manageable toxicity profiles. This review summarizes the preliminary clinical findings associated with the four strategies and outlines ongoing and future randomized studies of topotecan in front-line ovarian cancer. The Oncologist 2002;7(suppl 5):46-55 The Oncologist 2002;7(suppl 5):46-55 www.TheOncologist.com

show abstract

Section: Sequential Doublets Of Topotecan/paclitaxel With Platinummentioning

confidence: 99%

Section: Sequential Doublets Of Topotecan/paclitaxel With Platinummentioning

confidence: 99%

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Coleman¹

2002

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Some studies have suggested that hepatotoxicity is also a major dose-limiting side effect of CDDP-based chemotherapy [8,9]. It is widely used for the treatment of several human malignancies, including head and neck cancers [10] , testicular cancer [11], small-cell [12] and non-small cell lung cancer [13], ovarian cancer [14]. CDDP has serious side effects, such as ototoxicity, nephrotoxicity and hepatotoxicity [15,16].…”

Section: Introductionmentioning

confidence: 99%

Influence of L-arginine on Cisplatin-Induced Hepatotoxicity in both normally Fed and Protein Malnourished Rats

El-Hamid¹,

Ali²,

Ahmed³

et al. 2016

IOSR

View full text Add to dashboard Cite

“…The third agent can be applied as consecutive chemotherapy (7), consolidation chemotherapy (8), or combination chemotherapy. Combination chemotherapy has been most thoroughly studied.…”

Section: Introductionmentioning

confidence: 99%

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

Özgül¹,

Köse²,

Keskin³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

Reactions of N -isocyaniminotriphenylphosphorane with 2-oxopropyl benzoate (or 2-oxopropyl 4-bromobenzoate) in the presence of 3-phenyl-2-propynoic acid and primary amines proceeded smoothly at room temperature and in neutral conditions to afford sterically congested 1,3,4-oxadiazole derivatives in high yields. The reaction proceeded smoothly and cleanly under mild conditions and no side reactions were observed.

show abstract

Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study

Abstract: Sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin are feasible. The efficacy data in this suboptimal group of patients has encouraged us to proceed with a randomized study based on this approach.

Cited by 60 publications

References 17 publications

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Influence of L-arginine on Cisplatin-Induced Hepatotoxicity in both normally Fed and Protein Malnourished Rats

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

Contact Info

Product

Resources

About